Cutia Therapeutics
HHKEX:24870.67
HKD
-0.05
(-6.94%)
ISIN
KYG2606C1006
CUSIP
G2606C100
Return %
Stock
S&P 500
1Y
-91.86
14.20
3Y
-96.85
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Le Le Zhang
- Full Time Employees
- 304
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Huanzhi Building Shanghai SH China 200070
- IPO Date
- Jun 12, 2023
- Website
- cutiatx.com
- Similar Companies
- Business
- Cutia Therapeutics (2487.HK), an investment holding company incorporated in the Cayman Islands in 2019 and headquartered at 20/F, Huanzhi Building, 436 Hengfeng Road, Jingan District, Shanghai, China, engages in the research, development, manufacture, and commercialization of dermatology products targeting scalp diseases and care; skin diseases and care; topical anesthesia; and localized adipose accumulation management primarily in the People's Republic of China, Hong Kong, with manufacturing in Wuxi, Jiangsu and R&D centers in Shanghai and Beijing. The company leverages its proprietary CATAME technology platform to develop creams, sprays, ointments, aerosol foams, and other topical dosage forms, with a pipeline of 11 products including two marketed products, five clinical-stage candidates, and four preclinical assets. Core approved products comprise CU-40102, the first global topical finasteride spray approved by China's NMPA in June 2025 and Hong Kong's Department of Health in August 2025 for androgenetic alopecia in males via localized 5-alpha reductase inhibition with reduced systemic exposure versus oral formulations; and CU-10201, the first global topical 4% minocycline foam with NMPA priority review approval in November 2024 for moderate-to-severe non-nodular acne vulgaris in patients aged nine and older, offering lower side effects, drug resistance, and improved compliance over oral antibiotics. Key pipeline assets include CU-20401, a recombinant mutant collagenase in Phase II for submental fat reduction demonstrating statistically significant efficacy, dose-response trends, and favorable safety with no serious adverse events; CU-30101, a lidocaine-tetracaine cream with NMPA marketing application accepted in July 2024 post-Phase III equivalence to Pliaglis for surface dermatologic anesthesia; CU-10101, a non-hormonal small molecule in Phase I for mild-to-moderate atopic dermatitis since September 2024; and scalp candidates such as CU-40101, CU-40103, and CU-40104. Cutia Therapeutics recently raised HK$240.26 million in August 2025 through a 9.05% share placement at HK$8.40 per share to fund clinical trials, including CU-20401 Phase III advancement, commercialization of approved products, pipeline progression, and market expansion amid liquidity strengthening; terminated U.S. Phyto-C agency in H1 2025 to prioritize higher-return domestic launches like CU-40102 and CU-10201; activated GMP facilities in Wuxi with three production lines for creams, ointments, aerosols, and foams since 2023; and repurchased 1.3626 million shares in 2024 for treasury incentives. The company operates integrated capabilities from demand identification through clinical trials, regulatory approvals, manufacturing, and multichannel marketing via e-commerce platforms like Tmall and JD, social media, and hospital partnerships, serving diverse patient needs with 298 employees as of June 2025.